NITROLINGUAL (nitroglycerin) by Pfizer is (no), which activates guanylate cyclase, resulting in an increase of guanosine 3',5'-monophosphate (cyclic gmp) in smooth muscle and other tissues. First approved in 1985.
Drug data last refreshed 57m ago · AI intelligence enriched 57m ago
NITROLINGUAL is a sublingual aerosol formulation of nitroglycerin, a nitrate vasodilator approved in 1985 for acute angina relief. It works by releasing nitric oxide (NO) to activate guanylate cyclase, increasing cyclic GMP in smooth muscle and triggering vasodilation. This mechanism provides rapid symptom relief in patients experiencing acute coronary events.
Product approaching loss of exclusivity in 2029 with minimal Part D claims signals a mature, low-volume franchise facing significant generic erosion and reduced team expansion opportunities.
(NO), which activates guanylate cyclase, resulting in an increase of guanosine 3',5'-monophosphate (cyclic GMP) in smooth muscle and other tissues. This eventually leads to dephosphorylation of myosin light chains, which regulates the contractile state in smooth muscle and results in vasodilatation.
Nitrate Vasodilator
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
A Study to Learn About How Safe Nitroglycerin is and How it Affects the Body When Taken Along With Nurandociguat in People With Coronary Artery Disease
Vericiguat Drug-drug Interaction With Nitroglycerin in Stable Coronary Artery Disease Patients
Safety of Nitroglycerin for Field Treatment of STEMI
Treatment of Suspected Cholelithiasis With Nitroglycerin
The Effect of Nitroglycerin on the Intrauterine Device (IUD) Insertion Experience in Nulliparous Women
Worked on NITROLINGUAL at Pfizer? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access patent cliff timelines and LOE dates and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moLOE in ~3 years — strategic planning for patent cliff underway
NITROLINGUAL currently shows zero linked job openings, reflecting its mature lifecycle and small market footprint. Working on this product offers limited career growth; roles focus on defending market share against generics rather than expansion or innovation.